Abstract PD5-08: Tumor immunecell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients – An analysis of the GeparSepto trial - Fasching, P A; Denkert, C; Benz, S (Proceedings of the 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, USA. December 10-14, 2019)
et al.